(12) United States Patent (10) Patent No.: US 8,124,082 B2 Fong Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO8124082B2 (12) United States Patent (10) Patent No.: US 8,124,082 B2 Fong et al. (45) Date of Patent: Feb. 28, 2012 (54) HUMANIZED ANTI-BETA7 ANTAGONISTS 3.68 A 13 3. SEetC ren al. et al.1 AND USES THEREFOR 5,624,821 A 4/1997 Winter et al. 5,648,260 A 7, 1997 Winter et al. (75) Inventors: Sherman Fong, Alameda, CA (US); 5,658,727 A 8, 1997 Barbas et al. Mark S. Dennis, San Carlos, CA (US) 5,693,762 A 12/1997 Queen et al. 5,712.374. A 1/1998 Kuntsmann et al. 5,714,586 A 2, 1998 Kunstmann et al. (73) Assignee: Genentech, Inc., South San Francisco, 5,731, 168 A 3, 1998 Carter et al. CA (US) 5,733,743 A 3/1998 Johnson et al. 5,739,116 A 4, 1998 Hamann et al. (*) Notice: Subject to any disclaimer, the term of this 5,750,373 A 5/1998 Garrard et al. patent is extended or adjusted under 35 5,767.285 A 6/1998 Hamann et al. U.S.C. 154(b) by 119 days 5,770,701 A 6/1998 McGahren et al. M YW- y yS. 5,770,710 A 6/1998 McGahren et al. 5,773,001 A 6/1998 Hamann et al. (21) Appl. No.: 12/390,730 5,837.242 A 1 1/1998 Holliger et al. 5,877,296 A 3, 1999 Hamann et al. (22) Filed: Feb. 23, 2009 5,969,108 A 10/1999 McCafferty et al. 9 6,172,197 B1 1/2001 McCafferty et al. O O 6,300,080 B1 10/2001 Brenner et al. (65) Prior Publication Data 6,551,593 B1 4/2003 Ringler et al. 7,528,236 B2 5/2009 Fong et al. US 2009/0226437 A1 Sep. 10, 2009 7,687,605 B2 3/2010 Fong et al. 2001, 0046496 A1 11/2001 Brettman et al. Related U.S. Application Data 2005/OO95238 A1 5/2005 Brettman et al. (62) Division of application No. 1 1/219,121, filed on Sep. FOREIGN PATENT DOCUMENTS 2. 2005, now Pat. No. 7,528,236. EP O425235 B1 9, 1996 (60) Provisional application No. 60/607,377, filed on Sep. E. 338 3, 2004. WO WO93,06213 4f1993 WO WO93,21232 10, 1993 (51) Int. Cl. WO WO94/11026 5, 1994 A 6LX39/395 (2006.01) WO WO94,29351 12/1994 WO WO96,24673 8, 1996 (52) U.S. Cl. ............... 424/133.1; 424/141.1; 424/143.1; WO WO 98.06248 2, 1998 424/152.1; 424/156.1; 424/174.1 WO WO99,51642 10, 1999 (58) Field of Classification Search ........................ None WO WOOO.30681 6, 2000 See application file for complete search history. WO OOf 40604 T 2000 WO WOO 1/78779 10, 2001 (56) References Cited WO 2005/080432 A2 9, 2005 OTHER PUBLICATIONS U.S. PATENT DOCUMENTS Chen, et al., Journal of Molecular Biology—293:865-881 (1999). 4,137,230 A 1/1979 Hashimoto et al. Clark (Protein Engineering of Antibody Molecules for Prophylactic 4,151,042 A 4/1979 Higashide et al. and Therapeutic Applications in an, 1993, pp. 4-5). 4,248,870 A 2/1981 Miyashita et al. Holm, et al., Molecular Immunology 44:1075-1084 (2007). 4,256,746 A 3/1981 Miyashita et al. Malmborg, et al., Journal of Immunological Methods—183:7-13 4,260,608 A 4, 1981 Miyashita et al. (1995). 4,265,814 A 5, 1981 Hashimoto et al. Pascalis, et al., Journal of Immunology—169:3076-3084 (2002). 4,307,0164.294,757. A 12/198110/1981 Asai et al. Wu,u, et al., Journal of Molecular biologyBiology—294:151-162 294, (1999) 4,308,268 A 12/1981 Miyashita et al. Vajdos, et al., Journal of Molecular Biology 320:415-428 (2002). 4,308,269 A 12/1981 Miyashita et al. Andrew, D.P. et al., Distinct but overlapping epitopes are involved in 4,309.428 A 1/1982 Miyashita et al. O?37-mediated adhesion to vascular cell adhesion molecule-1, 4,313,946 A 2f1982 Powell et al. mucosal addressin-1, fibronectin, and lymphocyte aggregation' J. 4,315,929 A 2, 1982 Freedman et al. Immunol. 153:3847-3861 (1994). 4,317,821 A 3/1982 Miyashita et al. Baldwin et al., “Monoclonal Antibodies In Cancer Treatment' Lan 4.322,348 A 3, 1982 Asai et al. cet, The pp. 603-605 (Mar. 15, 1986). 4.331,598 A 5/1982 Hasegawa et al. Barbadillo, C. et al., “Anti-integrin immunotherapy in rheumatoid 3. E. A 3. 3. R et al arthritis: protective effect of anti-C4 antibody in adjuvant arthritis' 4,364,866 A 12, 1982 is a Springer Semin. Immunopathol. 16:427-436 (1995). 4,371.533. A 2, 1983 Akimoto et al. (Continued) 4.424,219 A 1, 1984 Hashimoto et al. E. A E. E. et Set 1 Primary Examiner — Karen Canella 486,567 A 3, 1989 E. (74) Attorney, Agent, or Firm — Jennifer L. Davis 4,970,198 A 11, 1990 Lee et al. (57) ABSTRACT 4,975,278 A 12/1990 Senter et al. 5,053,394 A 10, 1991 Ellestad et al. The invention provides therapeutic anti-beta7 antibodies, 5,079,233 A 1/1992 Lee et al. compositions comprising, and methods of using these anti 5,208,020 A 5, 1993 Chari et al. bodies. 5,416,064 A 5, 1995 Chari et al. 5,580,717 A 12/1996 Dower et al. 14 Claims, 22 Drawing Sheets US 8,124,082 B2 Page 2 OTHER PUBLICATIONS Jaffers et al., “Monoclonal Antibody Therapy, Anti-Idiotypic and Barbas III et al., “In Vitro Evolution of a Neutralizing Human Anti Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense body to Human Immunodeficiency Virus Type 1 to Enhance Affinity Immunosuppression' Transplantation 41(5):572-578 (May 1986). and Broaden Strain Cross-Reactivity” Proc. Natl. Acad. Sci. USA Jones et al., “Replacing the Complementarity-Determining Regions 91(9):3809-3813 (Apr. 1994). in a Human Antibody with Those From a Mouse” Nature 321:522 Carlsson, J. et al., “Protein Thiolation and Reversible Protein-Protein 525 (May 29, 1986). Conjugation” Biochemical Journal 173:723-737 (1978). Junghans et al., “Anti-Tac-H, a Humanized Antibody to the Carter et al., “Humanization of an Anti-p185' Antibody for Interleukin 2 Receptor with New Features for Immunotherapy in Human Cancer Therapy” Proc. Natl. Acad. Sci. USA 89(10):4285 Malignant and Immune Disorders' Cancer Research 50(5):1495 4289 (May 1992). Cepek, K.L. et al., “Integran O'B, mediates adhesion of T lympho 1502 (Mar. 1, 1990). cytes to epithelial cells”.J. Immunol. 150:3459-3470 (1993). Kanwar, J. et al., “f7 integrins contribute to demyelinating disease of Chari et al., “Immunoconjugates Containing Novel Maytansinoids: the central nervous system” J. Neuroimmunology 103: 146-152 Promising Anticancer Drugs' Cancer Research 52: 127-131 (Jan. (2000). 1992). Khazaeli et al., “Phase I trial of multiple large doses of murine Chothia, et al., “Canonical Structures for the Hypervariable Regions monoclonal antibody C017-1A. II. Pharmacokinetics and immune of Immunoglobulins' J. Mol. Biol. 196:901-917 (1987). response” J. Natl Cancer Inst.80(12):937-942 (Aug. 17, 1988). Cunningham and Wells, “High-Resolution Epitope Mapping of Kilger and Holzmann, “Molecular analysis of the physiological and hGH-Receptor Interactions by Alanine-Scanning Mutagenesis' Sci pathophysiological role of O-integrins' Journal of Molecular Medi ence 244: 1081-1085 (Jun. 2, 1989). cine 73(7):347-354 (Jul 1995). Doronina et al., “Development of potent monoclonal antibody Kilshaw and Murant, “Expression and regulation of f(p) integrins auristatin conjugates for cancer therapy' Nature Biotechnology on mouse lymphocytes: relevance to the mucosal immune system' 21:778-784 (2003). European Journal of Immunology 21 (10):2591-2597 (Oct. 1991). Duncan and Winter, “The binding site or Cld on IgG” Nature Kroneld, U. et al., “Expression of the mucosal lymphocyte integrin 322:738-740 1988. 3SupE37 and its Ligand E-cadherin in Salivary glands of patietns with Ebert, M. et al., “CD8+CD103+ T cells analogous to intestinal Sjogren's syndrome' Scand.J Rheumatol 27:215-218 (1998). intraepithelial lymphocytes infiltrate the pancreas in chronic Kunkeletal., “Rapid and EfficientSite-specific Mutagenesis Without pancreatitis' Am. J. Gastroenterol. 93:2141-2147 (1998). Phenotypic Selection” Methods in Enzymology 154:367-382 (1987). Erle et al., “Complete amino acid sequence of an integrin f3 Subunit Laberge, S. et al., “Role of VLA-4 and LFA-1 in Allergen-Induced (B) identified in leukocytes' Journal of Biological Chemistry Airway Hyperrespnosiveness and Lung Inflammation in the Rat' 266(17): 11009-11016 (Jun. 15, 1991). Fraker and Speck Jr., “Protein and cell membrane iodinations with a Am. J. Respir: Crit. Care Med. 151:822-829 (1995). sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a Leckie et al., “Sputum T lymphocytes in asthma, COPD and healthy diphenylglycoluril' Biochemical & Biophysical Research Commu subjects have the phenotype of activated intraepithelial T cells nications 80(4):849-857 (1978). (CD69+ CD103+)” Thorax 58:23-20 (2003). Francisco et al., “cAC10-vcMMAE, an anti-CD30 monomethyl Lee et al., “High-affinity human antibodies from phage-displayed auristatin E conjugate with potent and selective antitumor activity synthetic Fab libraries with a single framework scaffold'J Mol Biol. Blood 102: 1458-1465 (2003). 340(5):1073-1093 (Jul 23, 2004). Gallop et al., “Applications of Combinatorial Technologies to Drug Liu et al., “Eradication of Large Colon Tumor Xenografts by Tar Discovery Background and peptide combinatorial libraries' Journal geted Delivery of Maytansinolds.” Proc.